Breast cancer cells: focus on the consequences of epithelial-to-mesenchymal transition by Bong, Alice H. L. & Monteith, Gregory R.
Accepted Manuscript
Title: Breast cancer cells: focus on the consequences of
epithelial-to-mesenchymal transition
Authors: Alice H.L. Bong, Gregory R. Monteith
PII: S1357-2725(17)30066-3
DOI: http://dx.doi.org/doi:10.1016/j.biocel.2017.03.014
Reference: BC 5100
To appear in: The International Journal of Biochemistry & Cell Biology
Received date: 12-12-2016
Revised date: 16-3-2017
Accepted date: 18-3-2017
Please cite this article as: Bong, Alice HL., & Monteith, Gregory
R., Breast cancer cells: focus on the consequences of epithelial-to-
mesenchymal transition.International Journal of Biochemistry and Cell Biology
http://dx.doi.org/10.1016/j.biocel.2017.03.014
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.
 
 
Breast cancer cells: focus on the consequences of epithelial-to-mesenchymal transition 
Alice H.L. Bonga, Gregory R. Monteitha,b 
a, School of Pharmacy, University of Queensland, Brisbane, Queensland, Australia 
b, Mater Research, University of Queensland, Brisbane , Queensland, Australia. 
 
 
Cell Facts 
 Breast tumors are heterogeneous, and cancer cells within a tumor may exhibit 
epithelial and mesenchymal-like characteristics 
 Epithelial breast cancer cells can be induced to form mesenchymal-like cells during 
EMT  
 The mesenchymal phenotype as a consequence of EMT can be associated with 
increased resistance to current breast cancer therapies 
 
 
ABSTRACT  
Breast cancers are highly heterogeneous and successful treatment of those subtypes with a 
high frequency of metastases and resistance to clinically available therapies remains a 
challenge. An understanding of mechanisms which may contribute to this heterogeneity and 
generation of more resilient cancer cells is therefore essential. Epithelial-to-mesenchymal 
transition (EMT) is a dynamic two-way process that occurs during embryonic development 
and wound healing whereby epithelial cells can gain plasticity and switch to a mesenchymal-
like phenotype. EMT has received interest from cancer researchers due to its potential role in 
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processes important in cancer progression and metastasis. Recent evidence has revealed a 
clear association between EMT and resistance to therapeutics. Targeting of EMT and/or the 
mesenchymal-like phenotype may be a promising avenue for future therapeutic intervention. 
This review provides a brief summary of the functional consequences of EMT in breast 
cancer, with a focus on the mesenchymal-like phenotype. 
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1. Introduction  
Breast cancer is the most commonly diagnosed cancer in women worldwide (Chao et al., 
2010). The female breast is a complex organ comprised of a branched network of ducts and 
lobules with extensive structural remodeling after adulthood. Distinct cell types comprise the 
ductal and lobular network, with polarized luminal epithelial cells and basal myoepithelial 
cells residing on the supporting basal lamina. Other cell types such as adipocytes, fibroblasts 
and cells of the immune and vascular system form the surrounding stroma (Polyak and 
Kalluri, 2010). Within a tumor, breast cancer cells can present histologically as either 
epithelial or poorly-differentiated and mesenchymal-like (Pattabiraman et al., 2016; Polyak 
and Kalluri, 2010). Breast cancers are diverse and often heterogeneous in terms of 
morphology, molecular expression of common treatment targets, clinical disease progression 
and outcome. Based on the intrinsic molecular classification, breast cancers can be 
categorized into at least five distinct subtypes: luminal A and B, HER2-enriched, basal-like 
and claudin-low intrinsic subtypes (Prat et al., 2010; Sorlie et al., 2001). The luminal 
subtypes are generally epithelial-like whereas the basal-like and claudin-low subtypes are 
often enriched in mesenchymal markers and associated with poor prognosis (Prat et al., 
2010). Adding to this heterogeneity is the fact that breast cancer cells are dynamic, with 
microenvironmental factors capable of promoting the development of a more mesenchymal 
phenotype (Polyak and Kalluri, 2010), which is the focus of this review.  
 
2. Cell origin and plasticity  
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Mesenchymal breast cancer cells can be transformed from epithelial cells during induction of 
a developmental program termed epithelial-to-mesenchymal transition (EMT) (Nieto et al., 
2016; Thiery et al., 2009). EMT is important during normal embryonic development and 
wound healing, but is also implicated in cancer progression. EMT in breast cancer cells can 
be activated by a complex array of signals; these include cues from the tumor 
microenvironment such as hypoxia, and chemotherapeutic stress and autocrine and/or 
paracrine signals from stromal and immune cells such as transforming growth factor beta 
(TGF-β), insulin growth factor (IGF) and epidermal growth factor (EGF) ((Nieto et al., 2016; 
Thiery et al., 2009); refer to Fig. 1). These signals activate canonical EMT transcription 
factors including Twist, Snail and Zeb, which then produce a variety of key downstream 
molecular changes. EMT-activating transcription factors generally repress the expression of 
markers associated with the epithelial phenotype and facilitate acquisition of a mesenchymal 
phenotype. Indeed, the EMT gene expression signature enriched in expression of EMT-
inducing genes is closely associated with the mesenchymal-like claudin-low molecular 
subtype (Prat et al., 2010). Many studies assessing the downstream signaling and functional 
consequences of EMT in breast cancer have utilized experimentally inducible models of 
EMT, in particular TGF-β or EGF-mediated EMT models. The remodeling of specific 
signaling networks occurs in response to these inducers. An example is the remodeling of 
calcium signaling as evidenced by several in vitro studies (Davis et al., 2011; Davis et al., 
2014). This includes altered expression of the calcium-permeable channel P2X5 (Davis et al., 
2011) in an EGF-induced EMT model in the basal-like MDA-MB-468 breast cancer cell line, 
and the ability of inhibiting the calcium permeable ion channel TRPM7 (Davis et al., 2014) to 
suppress EGF-mediated EMT induction of vimentin expression in the same model.  
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EMT is a dynamic two-way process with the reverse process termed mesenchymal-to-
epithelial transition (MET) (Chao et al., 2010; Pattabiraman et al., 2016) Cells in the EMT-
MET spectrum can exist in intermediate states possessing both epithelial and mesenchymal 
traits to varying degrees (Nieto et al., 2016; Tan et al., 2014). These intermediate “hybrid” 
states are proposed to be highly plastic and can more readily revert to fully epithelial or 
mesenchymal phenotypes in response to local stimuli (Tan et al., 2014). Indeed, there is 
evidence for the presence of intermediate or “partial EMT” circulating breast tumor cells, and 
an EMT scoring tool predictive of clinical response to chemotherapy has recently been 
developed to quantify the extent of EMT in cells (Tan et al., 2014). 
 
3. Functions  
Epithelial cells undergo extensive molecular and cytoskeletal remodeling as a consequence of 
EMT. A key hallmark of EMT is loss of the cell adhesion molecule E-cadherin (Thiery et al., 
2009). During EMT there is a general downregulation of many epithelial markers with a 
concomitant gain in expression of molecules typically associated with mesenchymal cells 
such as N-cadherin and vimentin (Fig. 2) (Nieto et al., 2016; Thiery et al., 2009). 
Morphologically this results in a switch from polarized epithelial-like cells to spindle-shaped 
mesenchymal cells with front-rear polarity (Nieto et al., 2016; Thiery et al., 2009). The loss 
of E-cadherin also results in the activation of downstream EMT signaling pathways 
associated with malignant progression (Onder et al., 2008). The most commonly reported 
functional consequences of EMT in breast cancer cells are summarized below. 
4. Associated pathologies  
4.1 EMT and breast cancer cell invasion and migration  
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The acquisition of pro-invasive and migratory capabilities requires extensive cytoskeletal 
remodeling, involving actin polymerization and intermediate filaments. The formation of 
membranous protrusions called invadopodia, which are capable of releasing matrix 
metalloproteases (MMP) is important for cancer cell invasion. EMT-inducing transcription 
factors such as Twist and canonical proteins associated with the mesenchymal phenotype 
such as vimentin have been linked to some of these pro-invasive traits, as shown in various 
breast cancer cell lines including MCF7, MDA-MB-231 as well as mouse-derived mammary 
carcinomas (Asiedu et al., 2011; Schoumacher et al., 2010; Zhao et al., 2015). Vimentin in 
particular was shown to be essential for the elongation of mature invadopodia, which 
facilitates the breaching of MDA-MB-231 cells through the basement membrane to invade 
the surrounding stroma (Schoumacher et al., 2010).  
During EMT, the downregulation of cell-cell adhesion and increased detachment from 
underlying extracellular matrices allows increased cell motility and migratory capacity. EMT 
induction also activates signaling pathways involved in actin-myosin stimulation and cellular 
morphological changes essential for generating the traction force enabling cell migration. In 
particular, the upregulation of tyrosine kinase receptor AXL in mesenchymal cells induced by 
EMT and its association with enhanced cell motility and migration has been shown by several 
studies (Dang et al., 2015; Mak et al., 2016; Vuoriluoto et al., 2011).  During EGF-induced 
EMT in various breast cancer cell lines, EMT activation was shown to be associated with 
increased RhoA GTPase and Rac1 activity and enhanced breast cancer migration and 
invasion (Zhang et al., 2014). This migratory capability was confirmed in a recent in vivo 
study of EMT using fluorescent-labelled MMTV-PyMT transgenic mice (Beerling et al., 
2016).  These studies provided evidence that spontaneous EMT without the use of 
experimental inducers can generate mesenchymal cells with enhanced migratory capability, 
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although still not metastatic (Beerling et al., 2016). Although increased migratory potential is 
often attributed to the acquisition of mesenchymal characteristics, this was shown to not 
always be at the expense of complete loss of epithelial features, and cells with an 
intermediate phenotype are also highly migratory (Dang et al., 2015; Yu et al., 2013). 
Mammary tumor cells with a mesenchymal phenotype as a result of EMT can also remain 
non-migratory or temporarily “dormant”, as demonstrated in a recent study using an EMT-
driven fluorescent color-switching transgenic mouse model (Zhao et al., 2016). It is important 
to note that EMT may also facilitate the acquisition of other non-mesenchymal phenotypes 
capable of migration, such as an amoeboid phenotype (Zhao et al., 2016).  
 
4.2 EMT confers resistance to anoikis  
Detachment of breast epithelial cells from supporting extracellular matrix can activate an 
apoptotic program termed anoikis. As such, to detach and escape from the primary tumor and 
traverse through the circulation, breast cancer cells must overcome anoikis (Kumar et al., 
2011). EMT activation and downregulation of E-cadherin has been shown to confer anoikis 
resistance to breast cancer cells, whereas inhibition of EMT by silencing Twist reverses this 
effect (Onder et al., 2008; Kumar et al., 2011). This phenomenon can be partly explained by 
the reduced E-cadherin-mediated repression of survival signaling pathways such as the 
Wnt/β-catenin signaling pathway (Onder et al., 2008). Further evidence that EMT is activated 
and may be important for matrix attachment-independent cell survival comes from the 
observation that circulating breast tumor cells exhibit EMT-like plasticity, capable of 
switching between epithelial and mesenchymal phenotypes (Yu et al., 2013). The EMT-
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mediated protection against anoikis is also widely suggested to be one of the traits favorable 
for cancer cell metastasis (Kumar et al., 2011).  
 
 
4.3 EMT and breast cancer metastasis  
EMT has long been proposed to initiate the metastatic cascade, a series of events 
encompassing escape from the primary tumor to the seeding of tumors at distant secondary 
organs (Micalizzi et al., 2009; Thiery et al., 2009). Studies in support of this theory include 
various in vivo studies demonstrating the increased incidence of secondary metastases as a 
result of induced EMT (Micalizzi et al., 2009; Zhao et al., 2015). MET has also been 
suggested to be required for the seeding of tumor cells at the secondary metastatic site, as 
secondary tumor cells have been shown to be phenotypically epithelial and must exhibit a 
proliferative phenotype to establish a metastatic colony (Bonnomet et al., 2012). Clinical 
observations of EMT-like and mesenchymal gene expression signatures in circulating tumor 
cells and in cancers with poor prognosis and response to chemotherapy further supports the 
link between EMT and cancer progression (Bonnomet et al., 2012; Bulfoni et al., 2016). 
Despite these findings, other studies have suggested that EMT is not essential for breast 
cancer metastasis but is instead important in cancer cell adaptability to deleterious 
environmental stimuli such as hypoxia (Trimboli et al., 2008; Fischer et al., 2015). Using 
Cre-recombinant triple-transgenic mice with EMT-lineage tracing to detect cells that have 
undergone EMT, it was recently shown that breast cancer cells can metastasize independently 
of EMT, as established secondary tumors did not exhibit a fluorescent color-switch indicative 
of EMT (Fischer et al., 2015). These conflicting findings highlight the complexity of 
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assessing the significance of EMT in cancer metastases and the need for diverse 
physiologically-relevant methodologies and studies in other model systems (Nieto et al., 
2016). The contribution of the microenvironment in regulating EMT/MET and enhancing 
pro-invasive and metastatic signaling should be the focus of future studies assessing the 
potential link between EMT and metastasis (Nieto et al., 2016). 
4.4 EMT is associated with therapeutic resistance  
There is mounting evidence for the link between EMT and therapeutic resistance in various 
cancers. Acquisition of a mesenchymal phenotype was shown to protect breast cancer cells 
against many conventional anti-proliferative chemotherapy agents as well as radiation 
therapy (Asiedu et al., 2011). However, this effect could be limited to certain cancers and 
appears dependent on the degree of differentiation along the EMT spectrum, as cells that are 
"fully" mesenchymal may actually be more chemo-sensitive compared to "intermediate" 
mesenchymal phenotypes (Tan et al., 2014). EMT activation has also been shown to 
upregulate the CD44+/CD24- ratio, a marker of "stemness" in breast cancer cells (Asiedu et 
al., 2011; Mani et al., 2008). The link between EMT and "stemness" has been reviewed 
elsewhere (Nieto et al., 2016). Increased "stemness" may promote resistance to 
chemotherapy-induced cell death (Asiedu et al., 2011) as demonstrated in TGF-β induced 
EMT in a mouse mammary carcinoma cell line. Consistent with this, breast cancer 
populations that survive chemotherapy treatment have been shown clinically to have a more 
mesenchymal gene profile with enrichment in stem cell-like markers (Creighton et al., 2009). 
Using microarray analysis, patient tumors with EMT gene expression signatures were also 
shown to be less responsive to various clinically used chemotherapy agents (Taube et al., 
2010). These findings have been consolidated recently in an EMT-lineage tracing in vivo 
study by Fischer et al., showing that cells undergoing EMT are more resistant against 
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cyclophosphamide treatment (Fischer et al., 2015). The contribution of EMT to therapeutic 
resistance may also be partly explained by EMT-induced upregulation of multi-drug 
resistance genes such as the ABC drug transporters and drug metabolizing enzymes, 
enhancing removal of the drug from breast tumors (Asiedu et al., 2011; Fischer et al., 2015). 
 
5. Therapeutic opportunities and future directions 
The role of EMT in various cellular functions associated with cancer progression and 
therapeutic response suggests that pharmacological intervention of this process may represent 
a therapeutic target for breast cancer (Thiery et al., 2009). Given the association between an 
EMT-like signature and clinical prognosis, EMT-targeting agents could be used in 
combination with other chemotherapeutic agents. Agents that are selectively cytotoxic to the 
mesenchymal phenotype could be administered after chemotherapy, and these agents could 
be identified through the use of phenotypic-based drug-drug combination screens. A recent 
study which derived a generic EMT signature across different cancer types has identified 
potential targets upregulated in mesenchymal-like cells: AXL, immune checkpoint protein 
PD-L1 and PDGFR-A (Mak et al., 2016). Importantly, therapeutic sensitivity is increased 
with inhibition of these proteins (Mak et al., 2016). Alternatively, inhibiting EMT induction 
or inducing MET in breast cancer cells that may have acquired the mesenchymal-like 
phenotype may also reduce resistance towards chemotherapeutic agents. Reversing the stem 
cell-like, mesenchymal phenotype is another particularly attractive approach since this 
phenotype is closely associated with resistance to many conventional anti-proliferative 
chemotherapeutic agents (Pattabiraman et al., 2016). The recent identification of protein 
kinase A activators that can induce and maintain epithelial characteristics in mesenchymal-
like breast cancer cells and increase sensitivity to doxorubicin and paclitaxel treatments also 
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demonstrates the promising potential of targeting EMT (Pattabiraman et al., 2016). 
Nevertheless, each of the EMT-targeting strategies described has potential drawbacks. The 
induction of MET may facilitate secondary metastatic outgrowths due to the reversion to a 
potentially more proliferative, epithelial phenotype (Bonnomet et al., 2012, Nieto et al., 
2016). In addition, partial MET reversion may generate more therapeutically-resistant hybrid 
phenotypes, further complicating treatment (Tan et al., 2014). In summary, breast cancers are 
diverse and dynamic. A better understanding and assessment of the mesenchymal phenotype 
generated as a consequence of EMT is required and may open up a new avenue for the 
development of a novel set of therapeutic agents to combat breast cancer progression. 
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Figure Legends 
 
Fig. 1: EMT inducers and the EMT-MET spectrum. Epithelial cells can be induced to form 
mesenchymal-like cells as a result of EMT-activating stimuli such as chemotherapy, hypoxia, 
inflammation, metabolic stress, immune factors and growth factors such as IGF and EGF. 
The reverse can also occur via MET. Cells can undergo incomplete or partial EMT along an 
EMT spectrum of varying extents of epithelial or mesenchymal phenotypes; i.e. they are in 
highly plastic, intermediate EMT cell states and can become either epithelial or mesenchymal 
in response to local stimuli. Figure adapted from Thiery et al., (2009) and Nieto et al., (2016). 
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Fig. 2: Characteristics of epithelial and mesenchymal cells and commonly used experimental 
molecular markers. Epithelial-like cells (left) are characterized by cell-cell adhesions and 
presence of tight junctions, with apico-basal polarity and are typically proliferative and non-
motile. Mesenchymal-like cells (right) are characterized by a lack of cell-cell adhesions and 
have a fibroblast-like morphology with front-rear polarity. They have increased motility and 
are generally not as proliferative. Figure adapted and/or compiled from references: Asiedu et 
al., 2011; Beerling et al., 2016; Nieto et al., 2016 
 
